IGM Biosciences, Inc. (IGMS) NASDAQ
1.27
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
IGM Biosciences, Inc.
Address
325 East Middlefield Road
Mountain View, CA 94043
United States of America (the)
Phone
650 965 7873
Website
Sector
Healthcare
Industry
Biotechnology
Employees
149
First IPO Date
September 18, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Mary Beth Harler | Chief Executive Officer & Director | 754,539 | 1965 |
| Lisa L. Decker | Chief Business Officer | 555,088 | 1969 |
| Misbah Tahir | Chief Financial Officer | 678,268 | 1975 |
| Angus Sinclair | Executive Vice President of Research | 0 | N/A |
| Elizabeth Haanes | Senior Vice President of Intellectual Property | 0 | N/A |
| Eric W. Humke | Senior Vice President & Head of Clinical Research and Development | 0 | N/A |
| Marvin S. Peterson | Executive Vice President of Process Development & Manufacturing | 0 | N/A |
| Paul C. Graffagnino | Senior Vice President of Legal Affairs | 0 | N/A |
| Steven Weber | Senior Vice President, Corporate Controller & Principal Accounting Officer | 0 | 1977 |
| Harigopal | Senior Vice President of Group Operations | 0 | N/A |
| Elaine Sapinoso | Senior Vice President of Quality | 0 | N/A |
| Suzette Tauber | Chief Human Resources Officer | 0 | 1964 |
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
